COPD Patient Types

You can review various COPD patient types to see how nebulized therapy with BROVANA may benefit your COPD patients. There is also an overview of the GOLD guidelines and their recommendations for treating moderate to very severe COPD with long-acting bronchodilators.1

Click below to review 4 COPD patient types:

CAROL >

COPD patients with a low peak inspiratory flow rate (PIFR)

  • PIFR is the maximum amount of air that can be inhaled over the time course of 1 deep breath, measured in L/min
  • The more severe the patient's COPD and the older they are, the lower their PIFR2,3

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening.

LUKE >

COPD patients using a nebulized, short-acting bronchodilator ≥4 times daily

  • GOLD guidelines recommend long-acting bronchodilators for maintenance treatment1
  • Inhaled short-acting bronchodilators are recommended as needed for acute symptoms in all stages of COPD

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.

Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

RUTH >

COPD patients who have dexterity or other limitations, which may impact their ability to use a metered-dose inhaler (MDI)

  • Nebulized therapy requires no hand/breath coordination1,4
  • Deep breaths or breath holding not required with nebulized therapy1,4

BROVANA should not be used with other medications containing long-acting beta2-agonists.

NORMAN >

COPD patients who may benefit from the addition of a long-acting bronchodilator to their current tiotropium therapy

  • GOLD guidelines recommend adding 1 or more classes of long-acting bronchodilators when necessary1

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists.


Not actual patients


References:

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2010). http://www.goldcopd.org. Accessed March 15, 2011. 2. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36(2):213-218. 3. Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395-2401. 4. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127(1):335-371.